Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02152982 |
Recruitment Status :
Active, not recruiting
First Posted : June 2, 2014
Last Update Posted : July 28, 2022
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | December 1, 2021 |
Estimated Study Completion Date : | December 15, 2022 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
January 5, 2023 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):